Figure S10 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

Larissa Anastácio da Costa Carvalho; Nataliya Tovbis Shifrin; Manali S. Phadke; Michael F. Emmons; Ximo Pechuan-Jorge; Felix Mbuga; Oscar E. Ospina; Christopher Chow; Lillian Seu; Olivia L. Rose; Aparna Madhukeshwar Hegde; Nikhil I. Khushalani; Elsa Quintana; Keiran S.M. Smalley

doi:10.1158/2326-6066.31028342

Figure S10 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

2026 Open access

Read full text

Authors: Larissa Anastácio da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S. Phadke, Michael F. Emmons, Ximo Pechuan-Jorge, Felix Mbuga, Oscar E. Ospina, Christopher Chow, Lillian Seu, Olivia L. Rose, Aparna Madhukeshwar Hegde, Nikhil I. Khushalani

+2 more

Elsa Quintana, Keiran S.M. Smalley

DOI: 10.1158/2326-6066.31028342

Cited by: 0

Abstract

Supplemental Figure 10: Combination of Anti-PD1 + RMC-7977 alters cell interactions and signaling pathways compared to control and monotherapies. (A) Differential number of interactions and differential interaction strength comparing the control, anti-PD1, RMC-7977 and anti-PD1 + RMC-7977 groups. Blue is higher in control and red is higher in the indicated treated group. (B) Information flow for MHC-I, PDL2, PDL1, MHC-II, CXCL and IFN-II signaling pathways comparing control to indicated treated group anti-PD1, RMC-7977 and Anti-PD1 + RMC-7977 groups compared to control. Red represents the control and blue the indicated treated group

Fields of Study & Subjects

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

Publication details

Publication date: 8 January 2026